coin-img-ETHETH+0.70%coin-img-SOLSOL+2.43%coin-img-BTCBTC+0.30%coin-img-XRPXRP+2.74%coin-img-USDCUSDC+0.02%coin-img-ONDOONDO+26.03%coin-img-DOGEDOGE+4.10%coin-img-HYPEHYPE+0.60%coin-img-ETHETH+0.70%coin-img-SOLSOL+2.43%coin-img-BTCBTC+0.30%coin-img-XRPXRP+2.74%coin-img-USDCUSDC+0.02%coin-img-ONDOONDO+26.03%coin-img-DOGEDOGE+4.10%coin-img-HYPEHYPE+0.60%coin-img-ETHETH+0.70%coin-img-SOLSOL+2.43%coin-img-BTCBTC+0.30%coin-img-XRPXRP+2.74%coin-img-USDCUSDC+0.02%coin-img-ONDOONDO+26.03%coin-img-DOGEDOGE+4.10%coin-img-HYPEHYPE+0.60%coin-img-ETHETH+0.70%coin-img-SOLSOL+2.43%coin-img-BTCBTC+0.30%coin-img-XRPXRP+2.74%coin-img-USDCUSDC+0.02%coin-img-ONDOONDO+26.03%coin-img-DOGEDOGE+4.10%coin-img-HYPEHYPE+0.60%
user-avatar
WCVB

GLP-1 drugmakers face lawsuits alleging Ozempic and Zepbound caused permanent vision loss

AI Market Summary
GLP-1 drugmakers face a growing wave of lawsuits alleging Ozempic/Zepbound caused NAION-related permanent vision loss, while the FDA investigates a possible link. Although evidence is mixed and companies deny causality, litigation and potential label changes increase regulatory and legal overhang for the category. Near-term, this can pressure sentiment and raise risk premia for exposed pharma names amid heightened headline risk.
Impact level
● Medium
Affected assets
NCSKLLY2USD/USDT+3.31%
AI Insight · NCSKLLY2USD/USDTAI Insight
▼ Bearish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Manufacturers of GLP-1 drugs including Ozempic and Zepbound are facing lawsuits from patients who allege the medications caused permanent eye damage. The cases center on nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to sudden and often lasting vision loss. Nearly 100 NAION-related lawsuits have been filed in New Jersey since 2025, with another set of cases coming from Philadelphia, according to USA Today. Novo Nordisk has said semaglutide has a well-established safety profile backed by more than 58 million patient-years of postmarketing exposure.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Finance

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.